Actavis, Allergan shareholders bless merger; NICE favors Roche's new CLL med; Hikma posts 9% sales hike;

@FiercePharma: Stats, surprises and secrets revealed in annual drug-spending report. Story | Follow @FiercePharma

@EricPFierce: #FDA finds sends a warning letter to a second Novacyl API plant for retesting failed batches. News | Follow @EricPFierce

@CarlyHFierce: UPDATED: Just where does AbbVie expect to find $7B in Imbruvica sales? Article | Follow @CarlyHFierce

> Actavis ($ACT) and Allergan ($AGN) shareholders approved the companies' plans to merge, clearing the way for the $66 billion deal to close this quarter or early next. Release

> Cost-effectiveness watchdogs in England backed Roche's ($RHHBY) new leukemia drug, Gazyvaro, for use by the National Health Service. Report

> Jordan-based Hikma Pharmaceuticals posted a 9% hike in 2014 revenue, but said it expects growth at 6% for this year. Report

> The family of a Propecia user who committed suicide sued Merck ($MRK), alleging that the company failed to warn about the drug's potential to increase the risk of suicidal thoughts and behavior. Report

> The Danish biotech Bavarian Nordic said its U.S. smallpox vaccine sales fueled its first full-year profit in 5 years. Report

Medical Device News

@FierceMedDev: J&J hosts developer of novel skin cancer diagnostic at its new life science incubator. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Texas Medical Center adds 20+ device companies to its incubator. Story | Follow @VarunSaxena2

@EmilyWFierce: Get this week's edition of FierceDiagnostics, feat. OpGen's superbug Dx, new coverage decisions for $EXAS and more. Newsletter | Follow @EmilyWFierce

> Med tech moves in on Georgia: Varian, MiMedix to expand with up to 250 new jobs. Story

> J&J's DePuy Synthes recalls orthopedic surgical tool, but not ready to replace. News

> Olympus asked FDA to loosen its belt on cleaning guidelines for endoscope devices. Article

Biotech News

@FierceBiotech: From @FiercePharmAsia: Glaxo plants a flag in Singapore with CEO Witty on hand. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Amgen is canning 300 Onyx staffers, abandoning campus in latest biopharma purge. News | Follow @JohnCFierce

@DamianFierce: $PTX is buying the rights to $ZGNX's opioid Zohydro ER for $100M up front and up to $283.5M more. Release | FiercePharma story | Follow @DamianFierce

> The Fierce survey: Is this a biotech bubble or a sustainable bull market? More

> Glaxo plants a flag in Singapore with CEO Witty on hand. Item

> Intrexon partner AmpliPhi raises $13M for antibiotic R&D. News

Drug Delivery News

> Zohydro changes hands as Zogenix sells to Pernix for $100M-plus. More

> J&J partner Halozyme joins daratumumab trials with delivery tech in tow. Story

> Irish research center wins EU funding to study and develop transdermal delivery methods. News

> Will the third licensee of a buccal tablet for mouth fungus succeed where others have failed? More

> Developer of injectable osteoarthritis treatment postpones $75M IPO, raises $4M in debt instead. Article

Diagnostics News

> Philips, UC Irvine collaborate on diagnosing breast cancer among women with dense breasts. Story

> Exact Sciences signs on Anthem and Aetna to noninvasive colon cancer Dx. Report

> Quest and Personalis dive into exome sequencing for rare pediatric neurological disorders. Editor's corner

> J&J hosts developer of novel skin cancer diagnostic at its new life science incubator in Silicon Valley. More

> Navidea joins forces with Norgine to market cancer imaging Dx in EU. Article

Pharma Marketing News

> Lipitor keeps on selling, so Pfizer will keep on producing it in Ireland. Item

> Just where does AbbVie expect to find $7B in Imbruvica sales? Story

> Stats, surprises and secrets revealed in annual drug-spending report. More

> Onyx field reps spared in Amgen's 300-job bloodletting. Article

> Bayer puts cancer-fighting country crooner onstage to promote colonoscopies. Report

And Finally... The activist group Public Citizen is leading a charge against an FDA proposal to allow drugmakers to distribute peer-reviewed journal articles that may contradict a drug's official safety labeling. Report

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.